UNAIDS to slash workforce by more than half as funding by US and other big donors disappears
UNAIDS said 'the overall global AIDS response is facing a severe shock and many of the gains made in the past few decades are at risk of being reversed.' It said the restructuring follows an independent panel's recommendations calling for 'downsizing' its secretariat in Geneva while continuing to 'prioritize the most essential functions.' It said it would maintain its presence in 36 countries.
Drastic U.S. cuts in assistance under the current Trump administration, part of wider cuts for global health, strike perhaps the biggest blow ever to the world's efforts to fight HIV.
UNAIDS had previously warned that unless support to its HIV efforts are restored soon, more than 6 million additional people could die in the next four years and an additional 2,000 people per day could become infected with the virus that causes AIDS.
Employees were told at an internal town hall Tuesday that staff will be reduced to about 280 to 300 from about 600 currently, participants said.
UNAIDS officials were considering plans to move many posts to lower-cost locations where it already has offices: in Bonn, Germany; Nairobi, Kenya; or Johannesburg, South Africa — the country with the world's highest number of AIDS cases, agency spokesperson Charlotte Sector told the AP.
The agency was created in 1996, largely to address shortcomings in global HIV policy by another U.N. health agency, the World Health Organization, which continues to partially fund UNAIDS.
The United States, under the second Trump administration, has sharply reduced or paused international funding and support for many U.N.-related organizations.
In an interview with the AP in February in response to the U.S. cuts, UNAIDS Executive Director Winnie Byanyima said HIV infections could jump more than six times by 2029 if American support of the biggest AIDS program is dropped. She warned that more resistant strains of the disease could emerge.
Byanyima acknowledged some valid criticism regarding how HIV aid has been delivered and called it 'an opportunity to rethink and develop more efficient ways of delivering life-saving support.'
According to its website, support from the United States contributed more than 40% of the UNAIDS core program and non-core activities that totaled about $214 million in 2023, the most recent year listed. Other top contributors included the Netherlands, Sweden, Switzerland and the UK.
___
AP Medical Writer Maria Cheng in London contributed to this report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
7 minutes ago
- Politico
NIH plans heat up animal testing debate
WASHINGTON WATCH NIH Director Jay Bhattacharya elaborated on his strategic priorities for the National Institutes of Health on Friday — and drew criticism from some animal rights advocates. His strategy focuses on plans Bhattacharya and his boss, HHS Secretary Robert F. Kennedy Jr., have previously touted, like prioritizing nutrition research, advancing artificial intelligence, focusing on research reproducibility and shifting to solutions-based health disparities research. 'Taxpayer dollars are a finite resource, entrusted to NIH officials to invest in the nation's future,' Bhattacharya wrote in a statement published on NIH's website. 'By transparently establishing priorities and aligning our goals, we aim to demonstrate to the American public that we take this commitment seriously — and that we are doing all we can to honor their trust.' Falling short: But one priority area — moving away from animal testing in favor of alternative models and establishing an office to develop, validate and deploy those methods — was a sore point for animal rights group People for the Ethical Treatment of Animals. From PETA's vantage point, Bhattacharya's plan didn't go far enough. 'Dramatic change is essential, as we've seen how 'enhancing oversight' is a laugh-into-your-sleeve exercise, and 'considering non-animal methods' is a check box,' Kathy Guillermo, PETA's senior vice president of laboratory investigations, said in a statement. 'PETA urges him to remember that at the highest levels of the Trump administration, there are well-placed people rooting for NIH to break with career animal experimenters.' Animal testing state of play: In Congress, Sen. Rand Paul (R-Ky.) has been a persistent critic of animal testing at the health agencies and co-sponsored 2022 legislation with Sen. Cory Booker (D-N.J.) to permit drugmakers to use alternative methods to test their products. The health agencies have not shied away from the issue or from animal rights groups. Among the first policies that the NIH and the Food and Drug Administration announced this spring was a move away from animal testing for research and drug development. According to public calendar disclosures, FDA Commissioner Marty Makary met with PETA in July. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. The Pete & Bobby Challenge. HHS Sec. Robert F. Kennedy Jr. and Defense Sec. Pete Hegseth are challenging Americans to complete 50 pull-ups and 100 push-ups in under 10 minutes. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. EXAM ROOM Health insurance companies pay vastly different prices for health services from one another— even when they're performed at the same hospital. Aetna and UnitedHealthcare, two of the largest health insurers in the U.S., negotiated rates for six inpatient procedures that varied by an average ratio of 9.1 nationwide, according to a report by health data analytics firm Trilliant Health. Sticker shock: The median rate for a coronary bypass — with no catheterization or major complications — is $68,194. However, negotiated rates ranged from $27,683 to $247,902. Rates even varied within the same health system. For example, Aetna pays $166,288 for a patient with diabetes to have major heart bypass surgery using a minimally invasive technique at Jefferson Hospital in Philadelphia, while UnitedHealthcare pays about half that rate. The report also found no correlation between aggregate measures of cost and quality within a sample of 10 top-tier hospitals. Health systems that have similar quality in care might have wildly different negotiated rates for the same health services, according to the report. High-quality care? The data raises questions about whether insurers deliver the best value for patient care. 'It actually creates a fiduciary duty for the employers to be using this sort of information to make sure they're providing high-value health benefits to their employees,' said Allison Oakes, chief research officer at Trilliant Health, who worked on the report. She believes that this data could help reduce some price disparity. 'The hope is we start to see some of this variation in prices shrink, which, without changing quality or access, could actually reduce spending by quite a bit,' she said. Unintended effect: Ben Handel, professor of economics at the University of California, Berkeley, agrees that this kind of price transparency could lead to negotiated rates homogenizing. However, it might not necessarily bring down prices, he said. 'The other potential scenario is it raises prices,' he said. He notes that insurers' incentives vary by context. For example, when administrating a self-insured plan — where employers directly pay health costs and insurers provide only the network — they earn a percentage of each claim. 'Raising costs makes you more money,' said Handel.
Yahoo
20 minutes ago
- Yahoo
Marco Rubio Halts Gaza Visa Program Following Loomer's Explosive Revelations
The U.S. State Department, led by Secretary of State Marco Rubio, has announced an immediate halt to Palestinian visas after conservative activist Laura Loomer posted videos on X showing Gazans arriving at U.S. airports. Over the weekend, Loomer shared clips from an organization called 'HEAL PALESTINE,' showing Palestinians entering the U.S. through the group's medical program. She argued the arrivals posed a national security risk, claiming Muslim-majority countries should take care of Gazans instead. 'Heal Palestine is more than welcome to send the GAZANS to Qatar, Saudi Arabia, UAE, Jordan, or other Muslim countries for medical care. The issue is, these countries don't want them because they know the GAZANS have terrorist tendencies. Are we supposed to endanger American lives so we don't get called 'racist' by a Palestinian organization?' Loomer wrote in a post on X. Rubio confirmed the freeze during an interview on Face the Nation, saying, 'We are not going to be in partnership with groups that are friendly with Hamas. We're going to pause those visas … and we are going to pause this program and re-evaluate how those visas are being vetted and what relationship if any has there been by these organizations to the process of acquiring those visas.' Loomer later expressed frustration, writing on X: 'It should freak everyone out that it took a civilian blowing the whistle on GAZANS coming into our country with State Department-issued visas as opposed to a government employee or terrorism analyst at the CIA flagging this.' HEAL Palestine pushed back, stressing the initiative is a medical treatment program, not a refugee resettlement effort. 'Guided by human and American values, HEAL is committed to offering hope and healing to the few young lives we can reach,' the group said in a statement. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?
Diabetes patients in the US will now be able to purchase Ozempic for half its usual cost. Novo Nordisk, a Danish pharmaceutical company, said on Monday that it would be providing the drug through its direct pharmacy service for $499 (£369) per month, instead of just under $1,000 per month. The drug giant said it had made a deal with healthcare firm GoodRx to make Wegovy, its obesity drug, available at this price in over 70,000 pharmacies nationwide. It comes after Novo Nordisk saw sales plummet last month, after competition ramped up in the US. The company said the profit warning came as a result of 'persistent use' of compounded – or copycat – versions of its drugs, as well as 'slower-than-expected market expansion and competition'. It has faced serious competition from Mounjaro, Eli Lilly's rival weight loss jab, as well as what it described as 'unsafe and unlawful mass compounding' in the market as weight loss and diabetes drugs have soared in popularity. Ozempic and Wegovy both contain glucagon-like peptide-1 (GLP-1). It works by stimulating insulin secretion, which is why it helps patients with type 2 diabetes, but it also signals fullness to the brain. Wegovy only triggers the GLP-1 receptor in the brian but Mounjaro works on both GLP-1 and GIP receptors, which can lead to more weight loss. In March, Novo Nordisk reduced the cost of Wegovy for cash-paying patients, but now people without health insurance will be able to purchase it for this price. Trump's critique The move comes just weeks after President Donald Trump criticised GLP-1 agonists for being more expensive in the US than in other countries, adding that he would 'slash the cost of prescription drugs' by 80 per cent. Last month, Trump wrote to pharmaceutical leaders demanding that they 'negotiate harder with foreign freeloading nations'. He said: 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He's since upped that number, saying he would cut drug prices up to '1,500 percent,' which is mathematically impossible without entering negative numbers. He also said that European nations were 'unfairly shifting the cost burden onto American patients' by using their healthcare services to put pressure on US pharma companies to accept lower prices. Novo Nordisk said that the price cut was unrelated to discussions with the US government. Pfizer CEO Albert Boula has said he and other pharma companies are in talks about making their drugs available at a lower cost. Will it impact the UK cost? In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump. In a statement, it said it would continue to focus 'on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most'. However, last week, weight-loss drugmaker Eli Lilly said it would increase UK prices by as much as 170pc due to concerns about unfair pricing. The company said obesity drug Mounjaro would rise in price from Sept 1 in order to address 'pricing inconsistencies compared to other developed countries, including in Europe'. The company's weight-loss jab will cost between £133 and £330 per injection (depending on dosage) in the UK. CheqUp, a weight-loss jab provider, reported that sales of Wegovy increased more than 500pc, following the Eli Lilly announcement.
